| 吉非替尼治疗非小细胞肺癌的疗效及安全性评价 |
| |
| 引用本文： | 陈美.吉非替尼治疗非小细胞肺癌的疗效及安全性评价[J].解放军保健医学杂志,2010(1):29-31. |
| |
| 作者姓名： | 陈美 |
| |
| 作者单位： | 山东省肿瘤防治研究院药剂科; |
| |
| 摘 要： | 目的评价吉非替尼（gefitinib）治疗晚期非小细胞肺癌（NSCLC）的疗效及安全性。方法48例晚期NSCLC患者给予吉非替尼250mg,1/d,口服,疗程2～8个月。回顾性分析其疗效及安全性。结果48例患者有效率35.4%（17/48）,其中完全缓解（CR）4.2%（2例）、部分缓解（PR）31.3%（15例）;临床控制率为68.8%（33/48）,其中有效（CR＋PR）35.4%（17例）,稳定（SD）33.3%（16例）;临床受益反应率为75.0%（36/48）。腺癌组有效率及临床控制率显著优于非腺癌组（P〈0.01）;男性患者有效率为23.5%（8/34）,女性患者有效率为64.3%（9/14）,两者比较有统计学差异（P〈0.01）。胃肠道不良反应发生率为81.3%（39/48）,其中腹泻为38.5%（15/39）;皮疹发生率为68.8%（33/48）。结论吉非替尼治疗晚期NSCLC疗效较好,不良反应轻微,值得临床进一步推广。
|
| 关 键 词： | 非小细胞肺癌 吉非替尼 疗效 安全性 |
Clinical curative effect and safety evaluation of gefitinib in the treatment of non-small cell lung cancer |
| |
| CHEN Mei.Clinical curative effect and safety evaluation of gefitinib in the treatment of non-small cell lung cancer[J].Journal Of Health Care And Medicine in Chinese Pla,2010(1):29-31. |
| |
| Authors: | CHEN Mei |
| |
| Institution: | Department of Pharmacy;Shandong Provincal Institute of Cancer Prevention and Treatment;Jinan 250117;China |
| |
| Abstract: | Objective To evaluate clinical curative effect and safty evaluation of gefitinib in the treatment of NSCLC(nonsmall cell lung cancer).Methods Fourty eight patients with advanced stage NSCLC were administrated Gefitinib 250 mg daily orally for 2-8months and analysed its curative effect and safty retrospectively.Results The total effective rate was 35.4%(17/48),including CR of 2 cases(4.2%)and PR of 15 cases(31.3%);the clinical control rate was 68.8%(33/48),including effectiveness of 17 cases(35.4%) and SD of... |
| |
| Keywords: | Non-small cell lung cancer Gefitinib Clinical curative effect Safety |
| 本文献已被 CNKI 维普 等数据库收录！ |
